Transforming Growth Factor-β Signaling Plays a Pivotal Role in the Interplay Between Osteosarcoma Cells and Their Microenvironment
Franck Verrecchia, Françoise Rédini

To cite this version:
Transforming Growth Factor-β Signaling Plays a Pivotal Role in the Interplay Between Osteosarcoma Cells and Their Microenvironment

Franck Verrecchia* and Françoise Rédini

UMR1238 INSERM, Université de Nantes, PHY-OS, “Bone Sarcomas and Remodeling of Calcified Tissues”, Medical School, Nantes, France

Osteosarcomas are the most frequent form of primary bone tumors and mainly affect children, adolescents, and young adults. Despite encouraging progress in therapeutic management, including the advent of multidrug chemotherapy, the survival rates have remained unchanged for more than four decades: 75% at 5 years for localized disease, but two groups of patients are still at high risk: metastatic at diagnosis (overall survival around 40% at 5 years) and/or poor responders to chemotherapy (20% at 5 years). Because these tumors are classified as “complex genomic,” it is extremely difficult to determine the signaling pathways that might be targeted by specific therapies. A hypothesis has thus emerged, stating that the particular microenvironment of these tumors may interfere with the tumor cells that promote chemoresistance and the dissemination of metastases. The stroma is composed of a large number of cell types (immune cells, endothelial cells, mesenchymal stromal cells, etc.) which secrete growth factors, such as transforming growth factor-β (TGF-β), which favors the development of primary tumors and dissemination of metastases by constituting a permissive niche at primary and distant sites. Rather than targeting the tumor cells themselves, which are very heterogeneous in osteosarcoma, the hypothesis is instead to target the key actors secreted in the microenvironment, such as TGF-βs, which play a part in tumor progression. In the last decade, numerous studies have shown that overexpression of TGF-β is a hallmark of many cancers, including primary bone tumors. In this context, TGF-β signaling has emerged as a crucial factor in the cross talk between tumor cells and stroma cells in poor-prognosis cancers. Secretion of TGF-β by tumor cells or stroma cells can effectively act in a paracrine manner to regulate the phenotype and functions of the microenvironment to stimulate protumorigenic microenvironmental changes. TGF-β can thus exert its protumorigenic function in primary bone tumors by promoting angiogenesis, bone remodeling and cell migration, and by inhibiting immunosurveillance. This review focuses on the involvement of TGF-β signaling in primary bone tumor development, and the related therapeutic options that may be possible for these tumors.

Keywords: osteosarcoma, transforming growth factor-β, microenvironment, bone, metastases
INTRODUCTION

Osteosarcoma (OS) is the most common malignant primary bone tumor, occurring above all in children, adolescents, or young adults with a median age of onset of 18 years. These tumors occur commonly in the metaphyseal region of the long bones, developing at sites of rapid bone growth (1). The World Health Organization classification of tumors of the soft tissue and bone defines osteosarcoma as a “malignant, bone-forming tumor, divided into several histological subtypes: chondroblastic, fibroblastic, osteoblastic, telangiectatic, or small cells” (2). Some of these histological forms have distinct molecular and biological behaviors. Most osteosarcomas are “conventional OS” (85%), defined as primary intramedullary high-grade malignant tumors in which neoplastic cells produce immature bone or osteoid tissue.

Current treatment associates surgery with combinational chemotherapy which cures at 5 years approximately 70% of patients with localized disease, with response to preoperative chemotherapy as the strongest predictor of overall survival (3). However, survival for patients with metastatic or relapsed disease has remained unchanged over the past 40 years, with an overall survival rate of about 20% at 5 years (4, 5). At the time of diagnosis, 20% of patients present with detectable lung metastases, but it has been estimated that undetectable metastases are present in 80% of cases (6).

New therapeutic options are therefore needed for this type of tumor.

OSTEOSARCOMA MICROENVIRONMENT: POTENTIAL THERAPEUTIC TARGETS

Conventional high-grade osteosarcomas are generally genetically unstable tumors with complex karyotypes (7). Rarity and genomic complexity, as well as intra-tumoral and intertumoral heterogeneity, have presented challenges for the molecular characterization of osteosarcomas. These tumors are characterized by chromosomal instability, with high levels of somatic structural variations and copy number alterations (8). Somatic mutations in both TP53 and RB1 are the most frequently reported (9, 10). Other mutated genes include RecQ protein-like 4, which encodes POT.

Chromosomal instability, with high levels of somatic structural variations and copy number alterations (8). Somatic mutations in both TP53 and RB1 are the most frequently reported (9, 10). Other mutated genes include RecQ protein-like 4, which encodes POT.
The vicious cycle between tumor and bone cells during osteosarcoma development. Osteosarcoma cells produce soluble osteolytic factors such as receptor activator of nuclear factor kappa-B ligand (RANKL), interleukin-11 (IL-11), IL-6, and tumor necrosis factor-α (TNF-α) that directly activate osteoclastogenesis, leading to bone degradation. Osteosarcoma cells also produce soluble factors, such as bone morphogenetic protein (BMP) or parathyroid hormone-related protein (PTHRp), which stimulate the production of RANKL by osteoblasts and therefore increase osteoclast activity. Osteoblasts are derived from mesenchymal stem cell in response to transcriptional factors such as Runx2 and osterix. Following bone degradation, the growth factors trapped in the bone matrix, such as transforming growth factor-βs (TGF-βs), are released into the bone microenvironment and stimulate both tumor growth and metastatic progression.

Transforming growth factor-βs thus activate the Smads cascade (Figure 2), known as the canonical TGF-β signaling pathway. Briefly, receptor-regulated Smads (R-Smads), including Smad2 and Smad3, are phosphorylated and activated by TβRI. Activated R-Smads then dissociate from the Smad anchor for receptor activation protein (30) and recruit the common mediator Smad (co-Smad), Smad4. This protein complex is translocated into the nucleus to regulate target gene expression. At the regulatory DNA binding sequence of genes, the R-Smad/co-Smad complex activates transcription through physical interaction and functional cooperation of DNA-binding Smads with sequence-specific transcription factors (29). The minimal Smad-binding element contains four base pairs, 5′-AGAC-3′, but binding to other G/C-rich sequences has also been reported (31). Interaction between the R-Smad/co-Smad complex and other transcription factors (either co-activators or co-repressors) generates a high-affinity protein-DNA complex to regulate gene expression. Several inhibitory mechanisms regulate the TGF-β signaling cascade. Of them, Smad7, induced by TGF-β (32), competes with R-Smads for binding to activated TβRI and thus inhibits R-Smad phosphorylation. Smad7 also has the ability to recruit E3-ubiquitin ligases (Smurf1 and Smurf2) to activate TβRI, resulting in receptor degradation (33, 34). Moreover, Smad7 may inhibit R-Smad phosphorylation.
recruit protein phosphatases to the receptor complex, resulting in its inactivation (35).

In addition to this canonical pathway, TGF-βs are also able to activate Smad independent or non-canonical pathways, including mitogen-activated protein kinases and phospholipase C-kinase/AKT (PI3K/AKT) signaling pathways (36). In this context, one of the first non-Smad effectors of the TGF-β receptor complex is TRAF6, implicated in the activation of TGF-β-activated kinase 1, capable of activating the SAP/JNK and p38-kinase pathways (37, 38). More recently, it has been shown that TRAF6 favors the formation of a TβRI/p85α complex, leading to activation of the PI3K/AKT cascade (39).

**TGF-β AND OSTEOSARCOMA**

Regarding carcinoma, it is widely accepted that TGF-βs act both as tumor suppressors in premalignant tumors and as tumor promoters in advanced tumors (15, 40–43) (Figure 3).

Briefly, TGF-β1 acts as a tumor suppressor mainly through its ability to inhibit cell proliferation both by inducing the expression of cyclin-dependent kinase inhibitors such as p21^Cip1 and p15^Ink4a, and/or by reducing the expression of proliferative drivers such as c-Myc and cyclin-D (44–46). In this context, alterations or mutations to TGF-β cascade members have been associated with several types of carcinoma (47, 48).

In contrast with carcinoma, it seems that TGF-β fails to inhibit mesenchymal cell proliferation, particularly in the case of osteosarcoma cells (49, 50) and that TGF-βs exert only protumoral properties in sarcomas through their pro-metastatic effects. In this context, we will focus in this chapter on the pro-metastatic properties of TGF-βs in osteosarcoma. In the last few decades, studies of TGF-βs expression in cancer have correlated TGF-β levels with the metastatic potential of tumors, suggesting that TGF-βs play a role in tumor progression. In osteosarcoma, TGF-β1 and TGF-β2 expression increase in the sera of patients compared to those of healthy donors (50). This increase in TGF-β production is correlated with high-grade osteosarcoma and associated with the presence of lung metastases (50–52). In addition, our previous results suggest that TGF-β is capable of targeting both tumor cells and their microenvironment. The secretion of TGF-βs by tumor cells or stroma cells can effectively act in an autocrine/paracrine manner to regulate the phenotype.

**FIGURE 3** | The tumor suppressor and protumoral properties of transforming growth factor-β (TGF-β) in carcinoma. Tumor suppressor properties: TGF-βs inhibit cell proliferation largely by inducing the expression of cyclin-dependent kinase (CDK) inhibitors such as p21^Cip1 and p15^Ink4a, and an upregulation of mesenchymal markers such as N-cadherin, fibronectin, and vimentin. These changes in gene expression are regulated by transcription factors such as Snail-1, Snail-2, ZEB-1, and ZEB-2. TGF-βs stimulate epithelial–mesenchymal transition (EMT). This process is associated with a loss or downregulation of E-cadherin, claudins, and occludins, and an upregulation of mesenchymal markers such as N-cadherin, fibronectin, and vimentin. These changes in gene expression are regulated by transcription factors such as Snail-1, Snail-2, ZEB-1, and ZEB-2. TGF-βs stimulate angiogenesis in part by stimulating platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) expression. TGF-βs favor cancer cell migration and invasion in part by increasing matrix metalloproteinase-2 (MMP) expression. TGF-βs exert immunosuppressive effects via the modulation of the activity or biology of immune cells such as T-cells, natural killer cells (NK-cells), macrophages, and dendritic cells.
The crucial role of transforming growth factor-βs (TGF-βs) in osteosarcoma tumor growth and metastatic dissemination. Following bone degradation, the TGF-βs trapped in the bone matrix are released and promote osteosarcoma growth and metastatic dissemination by targeting both osteosarcoma tumor cells and their microenvironment. TGF-βs target osteosarcoma cells: TGF-βs stimulate "epithelial–mesenchymal transition-like" (EMT), cell migration, and invasion in part by increasing matrix metalloproteinase-2 (MMP-2) expression. TGF-βs target tumor microenvironment: TGF-βs upregulate the expression of osteolytic factors such as receptor activator of nuclear factor kappa-B ligand (RANKL) and interleukin-11 (IL-11) and therefore stimulate bone osteolysis and the secretion of protumoral factors. TGF-βs upregulate platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) expression, and therefore angiogenesis. Finally, TGF-βs exert immunosuppressive effects by regulating immune cell proliferation and activity.

TGF-β Exerts Protumorigenic Functions by Targeting Tumor Cells: TGF-β and Epithelial–Mesenchymal Transition (EMT) or “EMT-Like” Phenomena

The switch in TGF-β properties during carcinogenesis has been associated with the ability of TGF-βs to induce the EMT process (53). This multi-step process, characterized by a decrease in epithelial properties and an increase in mesenchymal ones, promotes the invasiveness of cancer cells and contributes to the development of circulating tumor cells (43, 54). This cellular process involves different molecular and cellular modifications, including a loss of cell-to-cell interactions associated with a loss or downregulation of crucial components in the intercellular junction such as E-cadherin, claudins, occludins, and desmosomes. In parallel, an upregulation of mesenchymal marker expression, such as N-cadherin, fibronectin, and vimentin, is observed. These changes in gene expression are regulated by different transcription factors such as Snail-1, Snail-2 (Slug), ZEB-1, and ZEB-2, or Twist (53, 54). Various secreted factors, such as fibroblast growth factors, hepatocyte growth factor, Wnts, Hedgehog proteins, or TGF-βs, induce EMT or are implicated in EMT (55). The regulation of EMT by TGF-βs has been associated with Smad-dependent and Smad-independent signaling pathways (43, 56). In TGF-β-induced EMT, Smad proteins can induce the expression of transcription factors such as Snail, Slug, and Twist involved in the loss of E-cadherin expression, and in turn in the loss of the E-cadherin adhesion complex (55, 57). Interestingly, several other signaling pathways, such as the Wnt, Hippo, and Sonic Hedgehog cascades, cooperate with the Smad cascade to regulate EMT in many cancer cells (55).

Despite the fact that osteosarcoma arises from transformed cells of mesenchymal origin, numerous studies have demonstrated that an overexpression of EMT-transcription factors such as Snails, ZEBs, or Twist is involved in the pathogenesis of osteosarcoma, making possible an “EMT-like” phenomenon (Figure 4) that promotes the invasive properties of osteosarcoma cells and therefore the formation of metastases at distant secondary sites (58). Osteosarcoma tissues thus exhibit elevated Twist expression compared with non-tumorigenic osteochondroma tissue. In addition, metastatic osteosarcoma (grade III) shows an increase in Twist expression compared with non-metastatic osteosarcoma (grade I/II) (59). In this context, in vitro studies have demonstrated that Twist overexpression in SaOS2 osteosarcoma cells is associated with both an increase in cell invasive properties and osteosarcoma cell resistance to cisplatin (60). Similarly, Snail-2 is expressed in the three main histological subtypes of long bone osteosarcoma (osteoblastic, chondroblastic, and fibroblastic), and Snail-2 expression is statistically
correlated with tumor grade whatever the osteosarcoma subtype (61). Finally, the transcript and protein levels of ZEB-1 are significantly higher in osteosarcoma tissues when compared with normal bone tissues, ZEB-1 levels being increased in patients with lung metastasis (62).

Together, these results demonstrate that an “EMT-like” phenomenon may be associated with the pathogenesis of osteosarcoma. Although the role of TGF-β has not yet been fully defined in this EMT-like process, in vitro experiments have demonstrated that the ability of TGF-βs to promote this EMT-like phenomenon (63) may be associated with the pro-migratory effect of TGF-β1 on several osteosarcoma cell lines (50, 64–66). In vivo experiments, using molecular (overexpression of the Smad inhibitor, Smad7) and pharmacological (SD-208 and/or halofuginone) approaches, have demonstrated that TGF-βs affect the development of lung metastases in osteosarcoma (50, 67). This effect is associated in large part with the ability of Smad7, SD-208, or halofuginone to block the capacity of TGF-β1 to stimulate osteosarcoma migration and invasion (15, 50, 67).

**TGF-β Exerts Protumorigenic Functions by Targeting the TME: Angiogenesis, Bone Remodeling, and Immunosurveillance**

Tumors are heterogeneous tissues in which tumor cells are surrounded by and interact with a complex TME, composed of both cellular and non-cellular components. This TME plays a critical role in determining the fate of tumor cells during tumorigenesis and metastasis. Aberrant upregulation of TGF-β expression in the TME has thus been implicated in promoting cancer progression and metastasis (68–70). In this context, we will focus the following chapter on the role of TGF-β1 in tumor angiogenesis, bone remodeling, and modulation of the immune system.

**TGF-β and Tumor Angiogenesis**

Angiogenesis is a complex biological process that plays a crucial role in sustaining the microenvironment, growth, and metastatic potential of several tumors (71). Schematically, this process favors the formation of blood vessels, increasing the supply of nutrients and providing an entry point for the invasive cells (72). The proliferation, migration, and maturation of endothelial cells are critical steps involved in regulating the angiogenic process. A crucial primary cytokine that drives this process is the secreted vascular endothelial growth factor (VEGF) which stimulates the proliferation and migration of endothelial cells, and the formation of vessels (73–75). Other secreted cytokines, such as platelet-derived growth factor (PDGF), also play a major role in blood vessel formation by inducing vessel maturation mainly by increasing pericyte migration and the induction of pericytes coverage (70, 76). Regarding the role of TGF-β1 in angiogenesis, TGF-β1 KO mice display a phenotype that is defective in angiogenesis (77, 78). In addition, the loss of endothelial type I or type II TGF-β receptors in mice results in a decrease in vessel formation (79, 80). With regard to tumor angiogenesis, high circulating levels of TGF-β1 are correlated with increased tumor angiogenesis in many forms of cancer (41). Different experimental models for tumor progression, as well as data from human biopsies, have thus demonstrated that a high expression of TGF-β is associated with the expression of angiogenic factors (81) and correlates with the increase in new vessel formation (82, 83). Interestingly, TGF-β1 is able to increase VEGF (84) or PDGF (85) expression in many cancer cells, and therefore to induce tumor angiogenesis (86, 87).

For osteosarcoma pathogenesis (Figure 4), VEGF expression has been associated with microvascular density (88), and patients with high VEGF expression levels exhibit lower disease-free survival (89). In vitro studies revealed that U2OS osteosarcoma cells secrete a PDGF-like growth factor (90), and a malignancy-dependent co-expression of PDGF and PDGF receptors has been observed in the biopsies of osteosarcoma patients (91). Finally, in vivo experiments demonstrated that blocking TGF-β signaling by Smad7 overexpression in osteosarcoma cells or treating mice with the ALK5 inhibitor SD-208, reduces expression of both the endothelial marker CD146 and PDGF (50).

**TGF-β and Bone Remodeling**

Two cell lineages, the mesenchymal osteoblastic and hematopoietic osteoclastic lineages, are implicated in bone remodeling. Schematically, the osteoblasts and osteoclasts drive bone formation and resorption, respectively. The three mammalian isoforms of TGF-β (TGF-β1, -β2, and -β3) are found in bone (92). The role of these TGF-βs in skeleton development in general, and specifically during bone remodeling, is complex. In vitro, TGF-β1 stimulates the proliferation and migration of mesenchymal stem cells during the early stages of osteoblastogenesis, and inhibits both the differentiation of mesenchymal stem cells into osteoblasts, and the activity of osteoblasts in the late stages of osteoblastogenesis (15, 93–95). For osteoclastogenesis, TGF-β1 affects bone resorption in a dose-dependent manner (15, 92). In vitro, low doses of TGF-β1 stimulate the differentiation of osteoclasts, and high doses of TGF-β1 inhibit the differentiation of osteoclasts through modulation of RANKL and osteoprotegerin expression by osteoblasts (96). As a consequence, in vivo experiments indicate that TGF-βs favor bone resorption and destruction (15).

Interestingly, blocking the TGF-β signaling pathway in osteosarcoma cells reduces the bone osteolysis associated with tumor growth and, in turn, tumor progression. Indeed, in a xenograft murine model of osteosarcoma using human HOS or SaOS2, Smad7 overexpression in tumor cells inhibited the tumor-associated bone destruction by both promoting ectopic bone formation and preventing trabecular bone osteolysis (50). One hypothesis to explain this phenomenon is that blocking the TGF-β cascade in osteosarcoma cells inhibits the expression and secretion of the TGF-β target genes, such as RANKL and IL-11, which stimulate osteoclast activity (50).

One of the hallmarks of the extra cellular matrix in tumor progression is also upregulation of proteolytic enzymes such as MMPs (68, 69, 97). For osteosarcoma, several studies have shown that highly invasive osteosarcomas express higher levels of MMP-2 than weakly invasive tumors, and osteosarcoma cell invasion is associated with MMP-2 expression (98, 99). In addition, MMP-2 expression correlated with prognosis and response to chemotherapy (100, 101). Interestingly, blocking the TGF-β signaling pathway in osteosarcoma cells reduces the formation of lung metastases, mainly by inducing a decrease in MMP-2 expression in tumors. In addition, blocking the TGF-β cascade in
tumor cells inhibits the expression and activation of MMP-2 and the ability of TGF-β to stimulate osteosarcoma cell migration and invasion (50) (Figure 4).

TGF-β and the Immune System
Transforming growth factor-βs are secreted cytokines that have multiple immunosuppressive properties (102) via modulation of

### TABLE 1 | Transforming growth factor-β (TGF-β) inhibitors in clinical development in cancer (ClinicalTrials.gov).

<table>
<thead>
<tr>
<th>Drug</th>
<th>Targets</th>
<th>Trial number</th>
<th>Cancer</th>
<th>Clinical development phase</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TGF-β ligand inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fresolimumab (GC-10008)</td>
<td>panTGF-β</td>
<td>NCT00356460</td>
<td>Advanced Renal Cell Carcinoma or Malignant Melanoma</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NCT00923169</td>
<td>Advanced Renal Cell Carcinoma or Malignant Melanoma</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NCT01472731</td>
<td>Relapsed Malignant Glioma</td>
<td>II</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NCT01112293</td>
<td>Relapsed Malignant Pleural Mesothelioma</td>
<td>II</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NCT01401062</td>
<td>Metastatic Breast Cancer</td>
<td>II</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NCT02581787</td>
<td>Early Stage Non-small Cell Lung Cancer</td>
<td>I, II</td>
</tr>
<tr>
<td>Trabedersen (AP12009)</td>
<td>TGF-β2</td>
<td>NCT00844064</td>
<td>Pancreatic Neoplasms, Melanoma or Colorectal Neoplasms</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NCT00431561</td>
<td>Glioblastoma or Anaplastic Astrocytoma</td>
<td>II</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NCT00761280</td>
<td>Anaplastic Astrocytoma or Glioblastoma</td>
<td>III</td>
</tr>
<tr>
<td>Belagenpumatucel-L (Lucanix)</td>
<td>TGF-β2</td>
<td>NCT00676507</td>
<td>Advanced Non-small Cell Lung Cancer</td>
<td>III</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NCT01058785</td>
<td>Lung Neoplasm, Carcinoma, Bronchogenic</td>
<td>II</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NCT01279708</td>
<td>Lung Neoplasm or Advanced Cell Lung Cancer</td>
<td>III</td>
</tr>
<tr>
<td>Recombinant human granulocyte macrophage-colony stimulating factor (rhGMCSF/shRNAfurin vaccine)</td>
<td>TGF-β1,2</td>
<td>NCT01309230</td>
<td>Ovarian Cancer</td>
<td>II</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NCT01505166</td>
<td>Colon Cancer</td>
<td>II</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NCT01867086</td>
<td>Ovarian Cancer</td>
<td>II</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NCT01551745</td>
<td>Ovarian Cancer</td>
<td>II</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NCT01061840</td>
<td>Ewings Sarcoma, Non Small Cell Lung Cancer, Liver Cancer</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NCT01453361</td>
<td>Advanced Melanoma</td>
<td>I</td>
</tr>
<tr>
<td><strong>TGF-β receptor inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Galunisertib (LY2157299)</td>
<td>TβRI</td>
<td>NCT02734160</td>
<td>Metastatic Pancreatic cancer</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NCT02154646</td>
<td>Pancreatic Neoplasm</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NCT01722825</td>
<td>Advanced or Metastatic Neoplasm</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NCT02452006</td>
<td>Prostate Cancer</td>
<td>II</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NCT02538471</td>
<td>Metastatic Breast Cancer</td>
<td>II</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NCT02423343</td>
<td>Refractory or Recurrent Non-Small Cell Lung Cancer</td>
<td>II</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Recurrent, or Hepatocellular Carcinoma</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>NCT02034419</td>
<td>Neoplasm</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NCT01373164</td>
<td>Pancreatic Cancer</td>
<td>I, II</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NCT02672475</td>
<td>Triple-Negative Breast Carcinoma</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NCT02668712</td>
<td>Rectal Adenocarcinoma</td>
<td>II</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NCT02240433</td>
<td>Hepatocellular Carcinoma</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NCT03206177</td>
<td>Carcinoma of the Uterus or Ovary</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NCT02906337</td>
<td>Advanced Hepatocellular Carcinoma</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NCT01220271</td>
<td>Glioma</td>
<td>I, II</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NCT01882269</td>
<td>Recurrent Glioblastoma</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NCT01246986</td>
<td>Hepatocellular Carcinoma</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NCT01682187</td>
<td>Glioma</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NCT02178358</td>
<td>Hepatocellular Carcinoma</td>
<td>II</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NCT02734160</td>
<td>Metastatic Pancreatic Cancer</td>
<td>I</td>
</tr>
<tr>
<td>TEW-7197</td>
<td>TβRI</td>
<td>NCT02160106</td>
<td>Advanced Stage Solid Tumors</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NCT03143985</td>
<td>Multiple Myeloma</td>
<td>I</td>
</tr>
<tr>
<td>PF-03446962</td>
<td>ALK1</td>
<td>NCT02116894</td>
<td>Colorectal Cancer</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NCT00557856</td>
<td>Advanced Solid Tumors</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NCT01620970</td>
<td>Transitional Cell Carcinoma of Bladder</td>
<td>II</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NCT01337050</td>
<td>Stomach Cancer</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NCT01911273</td>
<td>Advanced or Metastatic Liver Cancer</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NCT01486368</td>
<td>Malignant Pleural Mesothelioma</td>
<td>II</td>
</tr>
</tbody>
</table>

Fresolimumab (GC10008) is an antibody capable of neutralizing TGF-β1,2,3. Trabedersen (AP 12009) is an antisense oligodeoxynucleotide specific to human TGF-β2. Belagenpumatucel-L (Lucanix) is a TGF-β2 antisense transgene, rhGMCSF/shRNAfurin vaccine is a dual-modulatory autologous whole cell vaccine (bi-shRNA furin and GMCSF autologous tumor cell vaccine), incorporating the rhGMCSF transgene and the bifunctional shRNA-furin to block pro-protein conversion to active TGF-β1,2. Galunisertib (LY2157299) is a TβRI inhibitor. TEW-7197 is an inhibitor of the protein serine/threonine kinase activity of TβRI. PF-03446962 is a monoclonal antibody against ALK1. IMC-TR1 is a monoclonal antibody against TβRI.
the activity or biology of several cells in the immune system, such as T-cells, natural killer (NK) cells, macrophages, and dendritic cells (41, 103, 104).

These immunosuppressive abilities of TGF-βs include inhibition of T-cell proliferation, inhibition of T-cell differentiation into cytotoxic T lymphocytes and helper T cells, and inhibition of the T-cell stimulatory functions of antigen-presenting cells (104). For example, in a mouse model expressing a dominant negative form of TGFRII restricted to CD4+ and CD8+ T-cells, an antitumor response is observed against melanoma progression (105).

The functional activation of NK cells, which play a crucial role in the antitumor response by recognizing and destroying tumor cells, is inhibited by TGF-β via different mechanisms (105). For example, TGF-βs antagonize the IL-15-induced cell proliferation associated with NK-cell activation and thus block the functional activation of NK-cells (106). The biological functions of the DC cells involved in the activation of the immune response, and therefore in determining the host response to primary tumor cells, are also regulated by TGF-β (104). For example, TGF-β increases the expression of inhibitor of differentiation 1 driving the switch from dendritic cell differentiation to myeloid-derived suppressor cell expansion during tumor progression (107).

Solid tumors are usually invaded by macrophages called TAMs. These TAMs are classically divided into two categories: M1 polarized macrophages, identified as antitumor cells, and M2 polarized macrophages, identified as protumor cells (108, 109). In this context, certain studies have demonstrated the ability of TGF-βs to drive the induction of macrophage polarization from M1 to M2 subtypes (110). All these immunosuppressive properties of TGF-βs induce tumor evasion from immune response (41, 68, 103, 104).

The immune environment of osteosarcoma is mainly composed of myeloid cells (monocytes, macrophages, and dendritic cells) and T-lymphocytes (111). Osteosarcoma cells control the recruitment and differentiation of immune-infiltrating cells, and establish a local immune tolerant microenvironment, allowing the tumor to grow (111).

While initial studies demonstrated that macrophages are associated with reduced metastasis and improved survival in high-grade osteosarcoma (112), recent studies have shown that TAMs are associated with better overall survival (113, 114). T-cells are the other cell population represented in the immune infiltrate in osteosarcoma (111). Recent studies have indicated that the CD8+/FOXP3+-ratio is a strong prognostic factor for osteosarcoma at diagnosis (115).

CONCLUSION AND CLINICAL RELEVANCE

In carcinoma, TGF-βs exhibit both tumor suppressor and protumoral properties, depending on the stage of the disease. In this context, it seems that the timing of therapies targeting TGF-βs needs to be considered with great precision. For sarcoma, and specifically osteosarcoma, TGF-βs mainly seem to exert protumoral properties by targeting both tumor cells and their microenvironment. It therefore appears that TGF-βs, major drivers for osteosarcoma, could be considered as promising therapeutic targets in this disease. In the last decade, different strategies targeting TGF-βs have been developed (Table 1), including anti-ligand antisense oligonucleotides, which are capable of binding human TGF-β2 mRNA (trabelseren), antibodies that target ligands or receptors, such as fresolimumab, a humanized mAB against TGF-β, and drugs against TGF-β receptor kinases, such as galunisertib (LY2157299, a TGFRII inhibitor) [reviewed in Ref. (116–118)].

With these strategies, certain trials have shown positive results. For example, trabekersen has been successfully tested in patients with recurrent or refractory high-grade glioma. This randomized, open-label, dose-finding phase IIb study evaluated the efficacy of trabekersen administered intratumorally at doses of 10 or 80 µM compared with standard chemotherapy (temozolomide or procarbazine/lomustine/vincristine) in patients with recurrent/refractory glioblastoma multiforme or anaplastic astrocytoma (AA). Analysis of the AA subgroup revealed a significant benefit regarding the 14-month tumor control rate for 10 µM trabekersen vs chemotherapy. In addition, the trend for the 2-year survival rate was for the superiority of 10 µM trabekersen vs chemotherapy (119). Concerning galunisertib, the clinical benefit was observed in 12 of the 56 patients with glioma (21.4%) (120). Most other clinical trials were negative or are still in progress. It should be noted that some drugs that block TGF-β activity have shown cardiotoxicity as side effects.

However, these strategies that target the TGF-β pathway could be considered and proposed in the therapeutic arsenal for osteosarcoma patients.

AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

ACKNOWLEDGMENTS

The figures were produced with the support of Servier Medical Art (www.servier.com).

FUNDING

This work was supported by the associations “Etoile de Martin” and “Imagine for Margo,” and by SFCE, the “Societe Française de lutte contre les cancers et leucemies de l’enfant et l’adolescent,” and the Fédération Enfant et Santé.


Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Verrecchia and Rédini. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.